November 18, 2026
Health news, explained with evidence
LIVE
Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine

Targeting Nrf2 Pathway May Help Overcome Drug Resistance in Liver Cancer

🔬 Research 2 min read 👁 8

Researchers have identified that inhibiting the Nrf2 signaling pathway can restore sensitivity to regorafenib in liver cancer cells that have developed resistance to standard treatments.

🔬Research

Key points

  • Liver cancer cells resistant to sorafenib often show cross-resistance to regorafenib.
  • Upregulation of the Nrf2 pathway is linked to this drug resistance.
  • Inhibiting Nrf2 in laboratory models restored the effectiveness of regorafenib.

A recent study published in Scientific Reports explores potential strategies to address treatment resistance in hepatocellular carcinoma (HCC), the most common form of primary liver cancer. While sorafenib is a standard systemic therapy for HCC, many patients eventually develop resistance, which also appears to limit the effectiveness of subsequent treatments like regorafenib.

Researchers at Ege University investigated the role of the Nrf2 pathway in these resistant cells. Using HuH-7 and Mahlavu cell lines, the team observed that cells resistant to sorafenib showed higher levels of Nrf2 expression. When the researchers suppressed the Nrf2 pathway, they observed a significant decrease in cell viability and migration, alongside an increase in markers associated with programmed cell death.

The study demonstrated that combining Nrf2 inhibition with regorafenib significantly reduced tumor growth in 3D spheroid models. These findings suggest that targeting the Nrf2 pathway could be a viable strategy to enhance the efficacy of current second-line therapies for patients whose cancer has progressed after initial treatment.

What to know: This study was conducted exclusively in vitro using cell cultures and does not involve human or animal subjects. As this is early-stage laboratory research, these findings cannot be applied to clinical practice without further investigation. Always consult with an oncologist regarding specific cancer treatment options.

Source Nature Health Sciences — nature.com/articles/s41598-026-79897-x ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.